Intermittent Theta-Burst Stimulation for Memory Modulation in a Patient With Mild Cognitive Impairment and Trigeminal Neuralgia.

I have a long standing interest in developing disease-modifying therapies for movement disorders, a major unmet clinical need. I work at the interface of neuroscience and neurology to apply mechanistic understanding of neurological disease to develop targeted neuromodulatory therapies and in the process further disease mechanisms and medical therapy.

While striving to provide excellent clinical care, I also have several research interests:

1. Establish novel diagnostic biomarkers along with new therapeutic targets in Alzheimer's Disease (AD) and comorbid Cerebral Amyloid Angiopathy. I currently serve as the Associate Biomarker Core lead in the Duke-UNC Alzheimer's Disease Research Center (ADRC). I am also the site Principal Investigator (PI) of a Biogen sponsored phase 2 clinical trial, CELIA (BIIB080), that targets AD-related tau through an Anti-sense oligonucleotide (ASO) mechanism. Additionally, I am the site PI of the ALNYLAM sponsored phase 2 clinical trial. This trial knocks down the expression of APP through an ASO mechanism to potentially treat Cerebral Amyloid Angiopathy (CAA).

2. Investigate a neurodevelopmental disorder, Tuberous Sclerosis Complex (TSC), which has the potential to provide insight into the pathophysiological mechanism of AD-related tau. I have published several papers on this subject and am currently the PI of the Ann B. Bussell award that is following TSC patients longitudinally to determine if TSC is an AD-related tauopathy. 

3. I am interested discovering new biomarkers to diagnose various neurodegenerative diseases. I am a co-Investigator with NCCU colleagues. We have published several new tau epitopes as potential biomarkers in diagnosing AD at earlier stages and have applied for several government funding mechanisms to continue this work. 

Dr. Peterchev directs the Brain Stimulation Engineering Lab (BSEL) which focuses on the development, modeling, and application of devices and paradigms for transcranial brain stimulation. Transcranial brain stimulation involves non-invasive delivery of fields (e.g., electric and magnetic) to the brain that modulate neural activity. It is widely used as a tool for research and a therapeutic intervention in neurology and psychiatry, including several FDA-cleared indications. BSEL develops devices for transcranial magnetic stimulation (TMS) and other forms of magnetic stimulation such as magnetogenetics that leverage design techniques from power electronics and computational electromagnetics to enable more flexible stimulus control, focal stimulation, and quiet operation. We also deploy these devices in experimental studies to characterize and optimize the brain response to TMS. Another line of work is multi-scale computational models that couple simulations of the electromagnetic fields, single neuron responses, and neural population modulation induced by electric and magnetic brain stimulation. These models are calibrated and validated with experimental neural recordings through various collaborations. Apart from understanding of mechanisms, we develop modeling, algorithmic, and targeting tools for response estimation, dose individualization, and precise localization of transcranial brain stimulation using advanced techniques such as artificial neural networks and machine learning. Moreover, BSEL is involved in the integration of transcranial brain stimulation with robotics, neuronavigation, intracranial electrophysiology recordings, and imaging modalities such as functional magnetic resonance imaging (fMRI) and electroencephalography (EEG), as well as the evaluation of the safety of device–device interactions, for example between transcranial stimulators and implants. Importantly, we collaborate widely with neuroscientists and clinicians at Duke and other institutions to translate developments from the lab to research and clinical applications. For over 18 years, BSEL has been continuously supported with multiple NIH grants as well as funding by DARPA, NSF, Brain & Behavior Research Foundation, Coulter Foundation, Duke Institute for Brain Sciences, MEDx, Duke University Energy Initiative, industry, and philanthropic gifts. Further, some of our technology has been commercialized, for example as ElevateTMS cTMS, or incorporated in free software packages, such as SimNIBS and SAMT. Dr. Peterchev received the John Rothwell Award in 2024 for “excellence in non-invasive brain stimulation research that stimulates further work at a higher scientific level” and was elevated to IEEE Fellow in 2026.

My research centers around the use of structural and functional imaging measures to study the shifts in network architecture in the aging brain. I am specifically interested in changes in how changes in structural and functional connectivity associated with aging impact the semantic retrieval of word or fact knowledge. Currently this involves asking why older adults have particular difficulty in certain kinds of semantic retrieval, despite the fact that vocabularies and knowledge stores typically improve with age.

A second line of research involves asking questions about how this semantic system is organized in young adults, understanding which helps form a basis for asking questions about older adults. To what degree are these semantic retrieval processes lateralized? What cognitive factors affect this laterality? How are brain structures like the corpus callosum involved in mediating distributed activation patterns associated with semantic retrieval?